ML-9 (ML9) is a novel, potent and selective myosin light chain kinase (MLCK) inhibitor, also inhibits Akt kinase and and stromal interaction molecule 1 (STIM1). ML-9 enhances the anticancer activity of docetaxel, suggesting its potential application as an adjuvant to existing anticancer chemotherapy. The complex effect of ML-9 on autophagy and indentified ML-9 as an attractive tool for targeting autophagy in cancer therapy through dual inhibition of both the Akt pathway and the autophagy.

纯度：≥98%

CAS：110448-31-2